RET and cancer: To confirm a mechanism of resistance, it is not sufficient for an oncogenic variant to be present simply at the time resistance emerges; for instance, PI3K signaling activation is not uncommonly observed in RET-altered cancers but does not appear to be associated with resistance to RET inhibitors (Rosen et al. 2022).